TYROBP and prostate cancer: CAR NK cells designed to target the prostate stem cell antigen (PSCA) on prostate cancer cells were modified with a CAR vector in which the CD28 transmembrane and costimulatory domains as well as the CD3ζ signaling domain were exchanged for DNAX-activation protein 12 (DAP12) transmembrane and intracellular signaling domains, which resulted in specific cytotoxicity against PSCA-positive tumor cell lines as compared to PSCA-negative tumor cells in vitro and in vivo.